Association of Metabolic Syndrome(MetS), ErectileDysfunction (ED) and LateOnsetHypogonadism (LOH) - 27/06/08
Résumé |
The world wide rapidly increasing incidence and prevalence of the MetS currently represents one of the most challenging world health issues. The MetS is characterized by central obesity, insulin resistance and type 2 diabetes, increased levels of triglycerides, and hypertension. Obesity seems to play a key role in the MetS,with visceral fat distribution as a special risk factor for cardiovascular disease (CVD). Notably, ED is highly prevalent in men with both CVD and MetS. ED may be the early clinical manifestation of a generalized vascular disease and carries an independent risk for cardiovascular events. Furthermore MetS is strongly associated with hypogonadism and testosterone treatment may be indicated to treat ED in these patients. Nevertheless the evidence that testosterone therapy is indicated in obese men to reduce complications is still limited and controlled studies are still lacking. However, testosterone therapy seems to improve insulin resistance and may slow down the development of type 2 diabetes. This review identifies potential pathophysiological links among MetS, ED and LOH and presents the clinical implications in terms of MetS, ED and LOH diagnosis, assessment of patient risk, and therapy.
Le texte complet de cet article est disponible en PDF.Vol 17 - N° S1
P. 30 - janvier-mars 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.